A novel, long-acting glucagon-like peptide receptor-agonist: Dulaglutide

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 363-386

  Gurung, Tara ^a   Shyangdan, Deepson S ^a   O'Hare, Joseph Paul ^a   Waugh, Norman ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Dulaglutide; Effectiveness; Glucagon like peptide analogue; Glycemic control; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; TASPOGLUTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DISEASE DURATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; FLATULENCE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THYROID CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 84940022669     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S34418     Document Type: Review

References (44)

1. Turner R, Cull C, Holman R. United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2): 136-145.
2. Internation diabetes federation (IDF). Diabetes Atlas. 6th ed. Brussels, Belgium: IDF; 2013. Available from: http://www. idf. org/diabetesatlas. Accessed December 1, 2014.
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32(1): 193-203.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140-149.
5. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004; 53(9): 2492-2500.
6. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993; 36(8): 741-744.
7. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2): 194-206.
8. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol. 2009; 70(3): 343-353.
9. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009; 160(6): 909-917.
10. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009; 26(9): 837-846.
11. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogs for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010; 10: 20.
12. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes: The Management of Type 2 Diabetes; NICE Clinical Guideline 87. London, UK: NICE; 2014. Available from: http://www. nice. org. uk/cg87. Accessed December 1, 2014.
13. European Medicines Agency (EMA). Trulicity. Summary of Product Characteristics. London, UK: EMA; 2014. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470. pdf. Accessed May 5, 2015.
14. European Medicines Agency (EMA). EPAR Trulicity. London, UK: EMA; 2014. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473. pdf. Accessed January 5, 2015.
15. Eli Lilly. FDA Approves Trulicity (Dulaglutide), Lilly's Once Weekly Therapy for Adults with Type 2 Diabetes. Indianapolis, IN: Eli Lilly; 2014. Available from: https://investor. lilly. com/releasedetail. cfm?ReleaseID=871658. Accessed October 1, 2014.
16. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogs for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011; (10): Cd006423.
17. National Institute for Health and Care Excellence (NICE). NICE CG66. Type 2 Diabetes (Partially Updated by CG87). London, UK: NICE; 2008. Available from: http://www. nice. org. uk/guidance/cg66. Accessed December 12, 2014.
18. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes. A National Guideline. SIGN 116. Edinburgh, Scotland: SIGN; 2010. Available from: http://www. sign. ac. uk/pdf/sign116. pdf. Accessed December 10, 2014.
19. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management of Type 2 Diabetes in Adults. NICE Guideline Draft for Consultation, January 2015. London, UK, NICE; 2015. Available from: http://www. nice. org. uk/Guidance/InDevelopment/GID-CGWAVE0612. Accessed February 10, 2015.
20. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomized, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951): 1349-1357.
21. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2). Diabetes. 2014; 63: A87.
22. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014; 37(8): 2149-2158.
23. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37(8): 2159-2167.
24. Jendle J, Rosenstock J, Blonde L, et al. Better glycemic control and less weight gain with once-weekly dulaglutide vs. once-daily insulin glargine, both combined with premeal insulin lispro, in type 2 diabetes patients (AWARD-4). Diabetes. 2014; 63: A246-A247.
25. Eli Lilly. A study in participants with type 2 diabetes mellitus (AWARD-2). Available from: https://clinicaltrials. gov/ct2/show/NCT01075282?term=NCT01075282&rank=1. NLM identifier: NCT01075282. Accessed May 30, 2015.
26. Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014; 37(8): 2168-2176.
27. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analog dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012; 29(10): 1260-1267.
28. Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled study. Endocr J. 2014; 61(10): 949-959.
29. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14(36): 1-248.
30. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008; (2): Cd006739.
31. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1498-1507.
32. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12): 2464-2471.
33. Philis-Tsimikas A, Del Prato S, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013; 15(8): 760-766.
34. Gale E. Incretin therapy: should adverse consequences have been anticipated? BMJ. 2013; 346: f3617.
35. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomized and non-randomized studies. BMJ. 2014; 348: g2366.
36. Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014; 348: g2780.
37. Montori VM. The safety of incretin based drugs. BMJ. 2014; 348: g2779.
38. Food and Drug Administration (FDA). Summary Review. Dulaglutide. Silver Spring, MD: FDA; 2014. Available from: http://www. accessdata. fda. gov/drugsatfda_docs/nda/2014/125469Orig1s000SumR. pdf. Accessed January 5, 2015.
39. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013; 3(1).
40. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011; 13(5): 394-407.
41. Gustavson SM, Chen D, Somayaji V, et al. Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011; 13(11): 1056-1058.
42. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014; 64(4): 731-737.
43. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes. 2014; 38(4): 269-272.
44. Bain SC, Skrivanek Z, Tahbaz A, Pechtner V, Adetunji O. Efficacy of long-acting once weekly dulaglutide compared with short-acting twice daily (bid) exenatide in patients with Type 2 diabetes: A posthoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly Administration of LY2189265 in Diabetes-1 (AWARD-1) trial. Diabetic Medicine. 2014; 31: 50.